ZIM
CLDX icon

Zacks Investment Management’s Celldex Therapeutics CLDX Stock Holding History

Zacks Investment Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-733
Closed -$40K – 600
2017
Q1 		$40K Buy
+733
New +$38.2K ﹤0.01% 632
2016
Q4 		– Sell
-755
Closed -$46K – 651
2016
Q3 		$46K Sell
755
-3,824
-84% -$238K ﹤0.01% 639
2016
Q2 		$302K Buy
4,579
+101
+2% +$6.41K 0.01% 500
2016
Q1 		$254K Buy
4,478
+1,807
+68% +$203K 0.01% 523
2015
Q4 		$628K Buy
+2,671
New +$582K 0.02% 384

Other funds holding CLDX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Zacks Investment Management's CLDX Position: Q2 2017 in Review

Zacks Investment Management sold out of Celldex Therapeutics (CLDX) in Q2 2017, closing a stake of 733 shares — an estimated $40K sold.

Zacks Investment Management first reported a position in CLDX in Q4 2015 and held it in 5 quarters. The position peaked at $628K in Q4 2015. 130 funds tracked by Wall St. Rank hold CLDX as of Q2 2017.

  • Zacks Investment Management reported no remaining Celldex Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Zacks Investment Management sold 733 Celldex Therapeutics shares in Q2 2017, an estimated $40K.
  • Zacks Investment Management first reported a position in Celldex Therapeutics in Q4 2015 and held it in 5 quarters.
  • Zacks Investment Management's Celldex Therapeutics position peaked at $628K in Q4 2015.
  • 130 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2017.

Based on Zacks Investment Management's 13F filing for Q2 2017, filed 14 Aug 2017.